HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Analysis of factors affecting time in therapeutic range control after warfarin administration.

Abstract
The protective efficacy of warfarin for cardiogenic cerebral embolism has been established. However, warfarin is generally administered to only approximately 35% of the atrial fibrillation patients who required warfarin therapy. It has been reported that international normalized ratio (INR) control was carried out appropriately in < 50% of such patients. Therefore, from the viewpoint of prevention of the onset and recurrence of embolism, the maintenance of a stable anticoagulant level is necessary. In warfarin therapy, in addition to INR control, time in therapeutic range (TTR) also markedly affects the efficacy of warfarin therapy. Therefore, we classified patients into two groups on the basis of the cutoff TTR ≥ 65% at which the inhibitory effect of warfarin on stroke has been observed. We aimed to examine the association between INR and TTR with the correction of the therapeutic efficacy of warfarin by analyzing the factors leading to poor TTR control. The most valuable finding of this study is that marked fluctuations of brain natriuretic peptide levels in patients with complication of heart failure was a risk factor for poor TTR control. Identification of the factors leading to the poor TTR control is useful for making the decision to switch to other anticoagulants, such as dabigatran or apixaban, or to continue warfarin by correcting risk factors in atrial fibrillation patients receiving long-term warfarin therapy.
AuthorsE Kose, S Arai, T An, A Kikkawa, T Aoyama, Y Matsumoto, H Hayashi
JournalDie Pharmazie (Pharmazie) Vol. 70 Issue 7 Pg. 494-8 (Jul 2015) ISSN: 0031-7144 [Print] Germany
PMID26373212 (Publication Type: Journal Article)
Chemical References
  • Anticoagulants
  • Warfarin
Topics
  • Aged
  • Anticoagulants (administration & dosage, therapeutic use)
  • Atrial Fibrillation (drug therapy)
  • Female
  • Humans
  • International Normalized Ratio
  • Male
  • Middle Aged
  • Risk Factors
  • Warfarin (administration & dosage, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: